Abstract: Ceralasertib (AZD6738) is a potent, orally bioavailable, and selective inhibitor of the Ataxia Telangiectasia and Rad3-related (ATR) kinase, a critical regulator of the DNA damage response (DDR) network. This review synthesizes current literature on the pharmacological profile and clinical potential of Ceralasertib, with a specific focus on its role in driving synthetic lethality and enhancing targeted therapy combinations. By disrupting replication stress tolerance and cell cycle checkpoints, Ceralasertib exhibits significant antitumor activity, particularly in malignancies harboring specific genomic vulnerabilities such as ATM deficiency or ARID1A alterations. Furthermore, preclinical and early-phase clinical data demonstrate its synergistic efficacy when combined with DNA-damaging chemotherapy, poly (ADP-ribose) polymerase (PARP) inhibitors, radiotherapy, and immune checkpoint inhibitors. Despite challenges related to dose-limiting hematological toxicities and the need for precise biomarker-driven patient selection, Ceralasertib represents a highly promising precision oncology strategy for overcoming therapeutic resistance and improving outcomes in difficult-to-treat solid tumors.
1. Introduction
The DNA damage response (DDR) system is a complex network of signaling pathways that detects and repairs DNA damage to maintain genomic stability or induces apoptosis when damage is irreparable [1]. A critical transducer kinase within this network is the Ataxia Telangiectasia mutated Rad3-related kinase (ATR). The ATR pathway is primarily responsible for coordinating the cellular response to replication stress (RepStress), stabilizing replication forks, inducing cell cycle arrest, and facilitating DNA repair [1][4]. Cancer cells, particularly those driven by oncogenes (e.g., MYC, RAS) or harboring defects in other DDR pathways (such as ATM or p53 mutations), often exhibit high levels of endogenous replication stress, making them heavily reliant on the ATR-CHK1 signaling axis for survival [1][2][4].
Ceralasertib (AZD6738) is a novel, orally active, and highly selective ATR kinase inhibitor developed to exploit these tumor-specific vulnerabilities [1][4]. The primary research direction for Ceralasertib centers on its ability to induce synthetic lethality in DDR-deficient malignancies and its synergistic potential in combination with other targeted therapies, genotoxic drugs, and immunomodulators [1]. This review comprehensively outlines the pharmacological activity, molecular mechanisms, current limitations, and future perspectives of Ceralasertib in precision oncology.
2. Pharmacological Activity
Ceralasertib demonstrates potent pharmacological activity by selectively inhibiting ATR kinase. In vitro studies have shown that AZD6738 inhibits ATR kinase activity with an IC50 of 1 nM and suppresses downstream CHK1 phosphorylation with an IC50 of 74 nM [4]. It effectively suppresses the proliferation of various solid and hematological cancer cell lines at concentrations below 1 μM [4].
The compound exhibits profound synthetic lethality in specific genomic contexts. For instance, AZD6738 shows enhanced cytotoxicity in ATM-deficient chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), and gastric cancer models [4]. It is also highly active against tumors with ARID1A (AT-rich interactive domain-containing protein 1A) loss-of-function mutations, which are common in gynecological and colorectal cancers [1]. Clinically, Ceralasertib has shown durable single-agent antitumor activity and is currently being evaluated in numerous Phase I and II trials across multiple indications, including metastatic triple-negative breast cancer (mTNBC), melanoma, pancreatic ductal adenocarcinoma (PDAC), and small cell lung cancer (SCLC) [1][3].
3. Molecular Mechanism of Action
The molecular mechanism of Ceralasertib is rooted in the disruption of the ATR-CHK1 axis. Inhibition of ATR prevents the stabilization of stalled replication forks and disables the G2/M cell cycle checkpoint. This forces cancer cells to undergo inappropriate mitotic entry with unrepaired DNA damage, ultimately leading to replication fork collapse, genomic instability, and mitotic catastrophe [1][4].
Synthetic Lethality: Ceralasertib exploits synthetic lethality primarily in ATM-deficient and p53-null malignancies. Because ATM and ATR share overlapping functions in DNA repair, the loss of ATM creates an overreliance on the ATR pathway. When ATR is subsequently inhibited by Ceralasertib, the cells lose their compensatory repair mechanisms, resulting in targeted cell death [1][2][3].
Combination with PARP Inhibitors: Ceralasertib synergizes strongly with PARP inhibitors (e.g., Olaparib). While this combination is highly effective in homologous recombination (HR)-deficient tumors, it can also sensitize HR-proficient tumors. High concentrations of PARP inhibitors accelerate replication fork progression, triggering ATR-mediated replication stress; concurrent ATR inhibition by Ceralasertib suppresses this response, leading to the accumulation of toxic PARP1-DNA complexes and double-strand breaks (DSBs) [1][3].
Combination with Chemotherapy and Radiotherapy: Ceralasertib amplifies the DNA damage induced by agents like gemcitabine, cisplatin, and FOLFIRINOX. For example, it blocks gemcitabine-induced CHK1 activation and prevents the accumulation of ribonucleotide reductase M2 (RRM2), leading to severe replication catastrophe [3]. It also acts as a potent radiosensitizer by abrogating radiation-induced cell cycle checkpoints [3][4].
Immunomodulation: ATR inhibition by Ceralasertib plays a significant role in activating the immune system. It increases tumor mutational burden and neoantigen load, and triggers the accumulation of cytosolic DNA. This activates the cGAS-STING pathway and type I interferon (IFN) responses, thereby remodeling the tumor microenvironment and sensitizing tumors to immune checkpoint inhibitors like durvalumab [1][3].
4. Structure-Activity Relationship (SAR)
While the provided literature extensively details the pharmacological efficacy and clinical applications of Ceralasertib, specific chemical Structure-Activity Relationship (SAR) data—such as the impact of distinct functional group modifications on target binding affinity—are not explicitly detailed in the reviewed texts. However, the functional outcome of its optimized chemical structure is evident in its profile as a highly potent, selective, and orally bioavailable small-molecule inhibitor. Its structural refinement allows it to achieve target modulation at nanomolar concentrations (IC50 of 1 nM for ATR and 74 nM for CHK1 phosphorylation) while maintaining sufficient bioavailability for oral administration in clinical settings [4].
5. Current Limitations
Despite its therapeutic promise, the clinical application of Ceralasertib faces several limitations:
Toxicity and Adverse Events: Because ATR is essential for managing replication stress in normal dividing cells, Ceralasertib can cause dose-limiting toxicities. Hematological adverse events are predominant, including grade 3/4 thrombocytopenia, neutropenia, leukopenia, and anemia, which complicate its combination with myelosuppressive chemotherapies [3][4].
Pharmacokinetic Variability: As an orally administered drug, Ceralasertib is subject to variable intestinal absorption among patients, which can affect free drug availability and overall compliance compared to intravenous alternatives [2].
Biomarker Dependency: Single-agent efficacy is generally limited to specific, biomarker-defined populations (e.g., ATM loss, ARID1A deficiency). However, accurately confirming these biomarkers in routine clinical practice remains challenging. For instance, distinguishing between ATM-low and ATM-null tumors is critical for predicting response, yet immunohistochemistry and mutation scoring for the large ATM gene are complex [2][3].
Sequence-Dependent Efficacy: In combination therapies, the sequence of drug administration can drastically alter efficacy and toxicity. For example, in PDAC models, DDR-proficient tumors respond best when Ceralasertib precedes Olaparib, whereas DDR-deficient models are more sensitive to an Olaparib-first sequence, complicating standard clinical trial designs [3].
6. Future Perspectives
The future development of Ceralasertib relies heavily on refining precision oncology strategies and optimizing combination regimens:
Biomarker Discovery and Validation: Identifying robust predictive biomarkers is paramount. Beyond ATM and ARID1A, emerging biomarkers such as Schlafen 11 (SLFN11) expression, TOPBP1 overexpression, and transcriptomic replication stress signatures hold promise for stratifying patients who will benefit most from ATR inhibition [2][3].
Optimized Dosing Schedules: To mitigate overlapping toxicities with chemotherapy and PARP inhibitors, future clinical trials are exploring alternative dosing strategies. Concepts such as sequential dosing, "Gap-schedule" protocols (administering the ATR inhibitor during the interval between chemotherapy doses), and short-term ATR inhibition following radiotherapy are being investigated to maximize tumor cell death while sparing normal tissues [1][2][3].
Expanding Combinatorial Approaches: Ceralasertib is poised to become a combinatorial backbone in oncology. Ongoing Phase II and III trials (e.g., the HUDSON and NLMT trials) are evaluating its potential to restore sensitivity to immunotherapy in PD-1/PD-L1 refractory patients [1]. Additionally, novel combinations with WEE1 inhibitors, polymeric fluoropyrimidines (e.g., CF10), and tumor-targeted DNA damaging agents are being explored to push replication stress beyond the threshold of cellular viability [2][3].
